Eli Lilly will acquire gene-editing startup Verve Therapeutics for up to US$1.3 billion to boost its pipeline beyond its blockbuster weight-loss and diabetes drugs.

A newly approved shot could soon help protect babies from respiratory syncytial virus (RSV), the top cause of hospitalization in US infants.